Is Cagrilintide Safe? Safety Profile 2026 — PeptidePrices

Q: Is Cagrilintide safe?

Cagrilintide has a safety rating of 7/10 in our methodology — good. Phase III trials show good tolerability; GI side effects; injection site reactions

Q: Is Cagrilintide FDA approved?

FDA status: Not FDA-approved (Phase III). PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Cagrilintide?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Cagrilintide listings for prices ranked by COA tier and $/mg.

Safety Profile

Cagrilintide

Updated today

Metabolic Research Peptide

7/10Good

How we score compound safety →

Primary use: GLP-1 / appetite research

Regulatory Status

Not FDA-approved (Phase III)

Safety Summary

Phase III trials show good tolerability
GI side effects
injection site reactions

Cagrilintide's 7/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider Retatrutide and AOD-9604 as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeLong-acting acylated amylin analog

Molecular Weight4,409 g/mol

Amino Acids37 (modified amylin)

CAS Number1415456-99-3

FormulaC₁₉₄H₃₁₂N₅₄O₅₉S₂

Storage

Lyophilized−20°C, long-term

Reconstituted2–8°C, within days

Avoid repeated freeze-thaw
Protect from light

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Cagrilintide

Full Cagrilintide profile Cheapest Cagrilintide deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.